GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (NAS:NEO) » Definitions » Cash-to-Debt

NEO (NeoGenomics) Cash-to-Debt : 0.59 (As of Mar. 2025)


View and export this data going back to 1996. Start your Free Trial

What is NeoGenomics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. NeoGenomics's cash to debt ratio for the quarter that ended in Mar. 2025 was 0.59.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, NeoGenomics couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2025.

The historical rank and industry rank for NeoGenomics's Cash-to-Debt or its related term are showing as below:

NEO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.07   Med: 0.67   Max: 3.42
Current: 0.59

During the past 13 years, NeoGenomics's highest Cash to Debt Ratio was 3.42. The lowest was 0.07. And the median was 0.67.

NEO's Cash-to-Debt is ranked worse than
58.8% of 216 companies
in the Medical Diagnostics & Research industry
Industry Median: 1 vs NEO: 0.59

NeoGenomics Cash-to-Debt Historical Data

The historical data trend for NeoGenomics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

NeoGenomics Cash-to-Debt Chart

NeoGenomics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash-to-Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.35 0.84 0.72 0.68 0.64

NeoGenomics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cash-to-Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.63 0.64 0.64 0.64 0.59

Competitive Comparison of NeoGenomics's Cash-to-Debt

For the Diagnostics & Research subindustry, NeoGenomics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeoGenomics's Cash-to-Debt Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NeoGenomics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where NeoGenomics's Cash-to-Debt falls into.


;
;

NeoGenomics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

NeoGenomics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

NeoGenomics's Cash to Debt Ratio for the quarter that ended in Mar. 2025 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NeoGenomics  (NAS:NEO) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


NeoGenomics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of NeoGenomics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


NeoGenomics Business Description

Traded in Other Exchanges
Address
9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. It operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Executives
Michael Aaron Kelly director C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., NEW YORK NY 10016
Warren Stone officer: President, Clinical Services 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Lynn A. Tetrault director 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913
Stephen M Kanovsky director 88 OLD YORK ROAD, NEW HOPE PA 18938
Anthony P. Zook director C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW CA 94041
David Brian Perez director 12100 6TH AVENUE, LAKEWOOD CO 80228
Neil Gunn director 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Jeffrey Scott Sherman officer: Chief Financial Officer 103 POWELL COURT, SUITE 200, BRENTWOOD TN 37027
Alicia C Olivo officer: General Counsel 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Elizabeth Floegel director 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Greg D Aunan officer: Chief Accounting Officer HMS HOLDINGS CORP., 5615 HIGH POINT DRIVE, IRVING TX 75038
Melody Harris officer: President, Enterprise Ops 4801 WEST BYRON PLACE, DENVER CO 80211
Christopher M Smith officer: Chief Executive Officer 125 CONSTITUTION DRIVE, MENLO PARK CA 94025
Shashikant Kulkarni officer: President of Lab Operations 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Vishal Sikri officer: President and CCO, Inivata 9490 NEOGENOMICS WAY, FORT MYERS FL 33912